Angiogenesis in glioblastoma is largely dependent on vascular endothelial growth factor (VEGF) signalling. Consistently, the VEGF coreceptor NRP1 promotes angiogenesis and tumour growth in gliomas. Here, we provide data showing that an innovative peptidic tool targeting the transmembrane domain of NRP1 efficiently blocks rat and human glioma growth in vivo. We show both in vivo and in vitro that the antitumour effect results from the anti-proliferative, anti-migratory and antiangiogenic properties of the compound. The proposed NRP1 antagonizing peptide is therefore a promising novel class of anti-angiogenic drugs that might prolong glioma patient survival. Our results finally show for the first time that the transmembrane domain of important signalling receptors can be antagonized in vivo thereby providing a new avenue towards the development of atypical antagonists with strong therapeutic potential.
Introduction
Glioblastoma multiform (glioma, grade IV astrocytoma) is one of the most severe and frequent brain tumours. The median survival time of patients is not exceeding 15 months due to the lack of efficient treatments. The highly invasive phenotype of tumour cells is associated to formation of new blood vessels favouring tumour growth (Jain et al., 2007) . Recent preclinical and clinical data suggest that anti-angiogenic strategies may be useful to fight glioma development (Jain et al., 2006; Xu et al., 2009) . To address the need of new strategies to interfere with glioma growth by inhibition of neovascularization, we tested a peptidebased inhibition of neuropilin-1 (NRP1). This transmembrane protein, initially described for its role during nervous system development (Bagri and TessierLavigne, 2002) , is a positive modulator of vascular endothelial growth factor receptor 2 (VEGFR2) and is thereby a crucial fine-tuning element of angiogenesis (Jocic and Staton, 1993; Hong et al., 2007) . Moreover, consistent with several descriptions of its importance in tumourigenesis and tumour progression (GuttmannRaviv et al., 2006) , NRP1 promotes human glioma progression (Hu et al., 2007) . Hence, recent data show that VEGF blockade upregulates inflammatory pathways and NRP1, thereby presenting NRP1 as a potential target for improving anti-VEGF therapy (Xu et al., 2009) . Our previous work showed that the transmembrane domain of NRP1 contains a GxxxG dimerizing motif required to trigger efficient signalling (Roth et al., 2008) . Genetic or peptide-based inhibition of the transmembrane domain appeared sufficient to block NRP1 oligomerization and subsequent biological functions. Here, we found in models of orthotopic and heterotopic brain tumours that synthetic peptides targeting the transmembrane domain of NRP1 (pTM-NRP1) inhibit rat and human glioma growth in vivo. This antitumour effect relates to the inhibition of VEGF-dependent cell migration and cell proliferation, and to anti-angiogenic effect of the peptide as shown in situ by the reduction of microvessels density and neoangiogenesis (Taguchi et al., 2004; Uzzan et al., 2004) both in rat and in human glioma. We confirmed this action mechanism by using an in vitro and in vivo angiogenesis assay. Overall, our data not only show that the use of peptides antagonizing NRP1 is a very potent therapeutic strategy to treat glioma, but also exemplify that the transmembrane domain of proteins is an outstanding target to design innovative drugs.
Results

pTM-NRP1 is an anti-angiogenic agent
Considering the important function of NRP1 in angiogenesis, we evaluated both in vitro and in vivo how addition of pTM-NRP1 would interfere with blood vessel formation. This hypothesis was supported by our previous results showing that pTM-NRP1 reduced VEGF165 binding to NRP1 (Roth et al., 2008) . First, we verified that pTM-NRP1 had no acute toxic effect on human umbilical vein endothelial cells (HUVEC cells; PromoCell GmbH, Heidelberg, Germany) grown 6 h in the presence of the peptides as seen in Figure 1a . Second, we monitored cell proliferation using MTT assay after 24 h incubation. This approach revealed that pTM-NRP1 or pTM-NRP1 mut (an inactive control peptide in which the three glycines of the dimerizing motif have been replaced by three valines) (Roth et al., 2008) had no effect on HUVEC cells proliferation in control culture conditions (low serum, low VEGF). However, pTM-NRP1 but not pTM-NRP1 mut prevented VEGF-induced HUVEC cells proliferation (Figure 1b) . We next examined the migration of HUVEC cells grown in a 3D matrix composed of chicken plasma coagulated with thrombin. This substrate allowed cells to migrate from microaggregates of HUVEC cells incubated with or without VEGF and peptides. As seen in Figure 1c , HUVEC cells formed chains of migrating cells on addition of 100 ng/ml VEGF165. Interestingly, this VEGF165-induced migration was abolished in cells treated with pTM-NRP1 but not in the case of pTM-NRP1 mut treatment. Consistently, the anti-angiogenic effect of pTM-NRP1 was revealed in the matrigel assay (Matrigel; Millipore, Molsheim, France) favouring tube formation. In our hands, we observed a dense network of endothelial cells forming tube-like structures within 4-6 h ( Figure 2) . Interestingly, the addition of pTM-NRP1 inhibited tube formation. The use of various concentrations of the peptide revealed a significant effect from 10 À8 M reaching a maximal inhibition with 10 À7 M (data not shown). Quantitative analysis of this antiangiogenic effect performed by counting number of tubes or network complexity (number of branch points or intersections) showed a threefold reduction of angiogenesis in the presence of pTM-NRP1. In all cases, pTM-NRP1 mut had no effect on tube formation (see Figure 2) . Hence, we confirmed the anti-angiogenic effect of pTM-NRP1 using the in vivo CAM (chick chorioallantoic membrane) assay. In this case, the addition of 20 mg/ml VEGF165 induced blood vessels formation and sprouting. Strikingly, VEGF165-induced blood vessels formation was abolished in the presence of pTM-NRP1 but not in the case of pTM-NRP1 mut treatment ( Figure 3) . Altogether, these results showed that pTM-NRP1 inhibits VEGF-induced endothelial cells proliferation and migration and subsequent proangiogenic effects. MTT assay performed at 6 h incubation revealed no acute toxicity of the TM peptides (a). Vascular endothelial growth factor 165 (VEGF165)-induced HUVEC was blocked by pTM-NRP1 but not by pTM-NRP1 mut (b). VEGF165-induced migration of HUVEC cells from microaggregates grown in chicken plasma was blocked by pTM-NRP1 but not by pTM-NRP1 mut (c).
Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al pTM-NRP1 stably integrates tumour cell membranes and blocks NRP1 function We next evaluated how pTM-NRP1 could be used as a therapeutic treatment in cancer. First, we focused on the rat glioma model C6 cell line (American Type Culture Collection (ATCC, Manassas, VA, USA) CCL-107) recapitulating characteristic features of human glioma (Wang et al., 2001; Grobben et al., 2002) . We verified that our clone of C6 cells expressed significant levels of NRP1 using both RT-PCR and immunocytochemistry ( Figure 4a ). Moreover, we determined that pTM-NRP1 integrates the membrane of C6 cells within 1 h using a biotinylated version of the peptide revealed with rhodamine-conjugated streptavidin (Figure 4b ). These control experiments also showed that significant amount of pTM-NRP1 is still detectable at the membrane after 24 h incubation. Long-term analysis of pTM-NRP1 membrane incorporation using confocal microscopy revealed cell-surface clearance of peptide after 96 h (data not shown). Consistent with our previous description of the action mechanism of the peptide (Roth et al., 2008) , we found in C6 cells that pTM-NRP1 altered oligomerization of NRP1 on addition of Sema3A (Figure 5a ), a semaphorin involved in glioma migration (Nasarre et al., 2009 ) and shown to promote glioma dispersal through an autocrine mechanism (Bagci et al., 2009) . Moreover, although not inducing acute toxicity in C6 cells (see Figure 5b ), the addition of pTM-NPR1 induced a significant reduction of cell proliferation (À32%, Po0.05, Figure 5c ). Interestingly, the reduction of the proliferative capacity of C6 cells when blocking the transmembrane domain of NRP1 was confirmed in flow cytometry analysis performed with C6 cells stably expressing a dominant-negative form of NRP1 (Roth et al., 2008 ) that also caused a significant reduction (À26.5%, Po0.05) of C6 cells proliferation (see Supplementary Figure 2 (Garcia-Verdugo et al., 1998) . The addition of pTM-NRP1 in the culture medium suppressed VEGF-dependent C6 cells migration (2% of aggregates presenting chains of migration, n ¼ 161, Figure 4c ) Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al whereas pTM-NPR1 mut did not prevent VEGF-induced chain formation (96% of aggregates presenting chains of migration, n ¼ 179, Figure 5d ).
Thus, pTM-NRP1 is able to block Sema3A-and VEGF-related NRP1 functions in C6 cells. This resulted in decreased proliferation and migration of the C6 tumour cells.
pTM-NRP1 prevents glioma growth in vivo
We further explored the therapeutic potential of pTM-NRP1 in a model of orthotopic brain tumour (Grobben et al., 2002) . We stained C6 cells with PKH26 (Sigma, Saint Quentin Fallavier, France) to easily determine tumour extent and cell dissemination by fluorescent examination of brain slices (see Supplementary Figure  1 ). We standardized our conditions to have comparable tumours 8 days after injections. For treatments, cells were incubated with the active peptides (pTM-NRP1 10 À8 M) before tumour cell transplantation for at least 2 h on ice in culture medium. We transplanted 10 6 cells per animal using a stereotaxic frame to implant the tumour cells in the striatum. In control conditions, we obtained large tumours often giving rise to secondary tumours developing at a distance of the injection site. This shows the highly invasive behaviour of these tumour cells often seen migrating along the corpus callosum (see Supplementary Figure 1 ; Grobben et al., 2002) . We used magnetic resonance imaging (MRI) to analyze tumour progression in control (three cases) and pTM-NRP1 (three cases) treated animals. As seen in Figure 6a , after 8 days, the growth of pTM-NRP1-treated C6 cells was dramatically reduced compared to control cells being almost not detectable in certain cases with MRI. To confirm these data, we extended the analysis to increase the number of cases and we included an additional Microphotographs and corresponding camera lucida drawing were obtained after 24 h incubation with phosphate-buffered saline (PBS) (1), VEGF165 (2), VEGF165 þ pTM-NRP1 (3) or VEGF165 þ pTM-NRP1 mut (4). The number of blood vessel in the region incubated with different solutions served to quantify the angiogenic effects. *Po0.05.
Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al control group of animals receiving cells preincubated with the mutated inactive version of NRP1 peptide (pTM-NRP1 mut 10 À8 M). The histological analysis of the brains confirmed that blocking NRP1 with pTM-NRP1 (12 cases) inhibits tumour growth (up to À80%) in a remarkably reproducible manner (12 out of 12 cases). In control experiments (no treatment of the cells, 12 cases or incubation with pTM-NRP1 mut , 7 cases), C6 cells developed large tumours with secondary implantations often lying at the ventricle border (see Figure 6b ). This reduction of tumour growth can be related to the inhibition of cell proliferation and cell migration observed in vitro.
Local and intraperitoneal administration of pTM-NRP1 inhibits glioma growth in vivo At this point, our data supported the use of pTM-NRP1 as a novel pharmacological agent to treat glioma. However, because tumour cells were preincubated with the peptide before intracranial transplantations, we had to verify the therapeutic potential in predeveloped tumours. We therefore decided to perform local injections of the peptides directly in the tumour surrounding. Unfortunately, we failed to perform this experiment in tumours implanted into the brain due to numerous animal deaths on additional injections and poor diffusion of the peptide from the injection point. Thus, we decided to use a heterotopic brain tumour model consisting in the graft of the tumour cells in the flank of athymic nude mice (Kelland, 2004) . This allowed us to perform multiple injections of the peptide around developing tumours and allowed the use of a human glioma cell line. In fact, the transmembrane domain of NRP1 is 100% conserved in mouse, rat or human. This, besides pointing out the importance of this domain from a phylogenic point of view, allowed us to use the same peptidic tool, targeting both the human tumour cells and the host blood vessels. We choose the glioma cell line U373MG expressing high level of NRP1 (Hu et al., 2007) (data not shown). To this end, we transplanted U373MG cells in mice and checked for tumour apparition after few days. We usually obtained visible tumours under the skin of animals within 4 days. At this point, we randomized mice in two groups receiving subcutaneous injections of phosphate-buffered saline (PBS) or 10 À7 M pTM-NRP1 in PBS for a period of 10 days. To further characterize evolution of individual tumours, we estimated tumour volume in blind condition every day (volume ¼ (a 2 Â b)/2, aob) (Hu et al., 2007) using a calliper on subcutaneous administration of first dose of treatments (PBS or 10 À7 M pTM-NRP1). As depicted in Figure 7a , the growth rate (final volume/initial volume) of U373MG tumours reached 7.9-folds in control conditions while not exceeding 3.6-folds in animals receiving daily local administration of pTM-NRP1 (Figure 7a) . Consistently, the determination of final tumour weight confirmed Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al the significant reduction of tumour growth (1.7±1.1 g in control n ¼ 19 versus 0.9 ± 0.7 g in pTM-NRP1-receiving group n ¼ 20, Po0.001, Figure 7b ). Control experiments conducted with C6 wild-type cells and C6 cells stably expressing a full-length NRP1 mutated in its transmembrane domain also showed a reduction of glioma growth when inhibiting the transmembrane domain of NRP1 (see Supplementary Figure 3) . Strikingly, we observed during U373 tumour resection a dramatic reduction of tumour perfusion in treated animals (see Figure 7c ). Although numerous and large blood vessels colonized the tumours in control conditions, rare and small vessels were seen in pTM-NRP1-treated animals. To further analyze the reduction of blood vessels formation in treated tumours, we performed histological analysis of tumour samples (from smallest, medium and largest tumours of the two groups). Quantification of blood vessels using isolectin-B4 revealed a sixfold reduction of blood vessels number in animals receiving pTM-NRP1 (16.4±6.5 vessel per mm 2 in control tumours versus 2.6 ± 1.5 vessels per mm 2 in pTM-NRP1-treated tumours, Po0.05). Similar results were obtained using CD31 (endothelial cells) or CD34 (neoangiogenesis) (Goldbrunner et al., 2000) as blood vessel markers (Figure 8) . Thus, the antitumour effect of pTM-NRP1 in human glioma can also be correlated to antiangiogenic effect.
Hence, we decided to test whether intraperitoneal (IP) injection of pTM-NRP1 might induce similar therapeutic effect. As a first step, we monitored the distribution of a rhodamine-conjugated peptide (Rhod-pTM-NRP1) using a live in vivo imaging system (Berthold, Thoiry, France). As seen in Figure 9a , we observed a large distribution of the peptide 15 min after injection. The tumour mass was clearly stained whereas low level of staining could be monitored in the brain. Interestingly, the histological examination of tumours from animals receiving IP injections of Rhod-pTM-NRP1 confirmed the distribution of the peptide in the tumour mass. A close examination showed staining of intratumour blood vessels accompanied by diffusion of the peptide in the surrounding tissue (Figure 9b ). This result therefore suggested that IP treatment could be used in the model of human glioma xenografts previously used for local administration of the peptide. Indeed, as depicted in Figure 9c , daily IP injections induced a 50% reduction of the tumour mass comparable to the effect obtained with local injection.
Discussion
As a conclusion, our data show that antagonizing the transmembrane domain of NRP1 is an outstanding strategy to inhibit tumour growth in vivo. In the case of Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al glioma, the observed reduction of tumour progression relates to the inhibition of VEGF-related proliferative and migratory promoting effects and defaults of neoangiogenesis. We have shown the anti-angiogenic property of pTM-NRP1 in two different models (matrigel assay and CAM assay). In all cases, we show that lack of tube formation or vessel formation and sprouting is not due to acute toxicity but due to the inhibition of endothelial cells proliferation and migration in response to VEGF. Moreover, pTM-NRP1 directly induces reduction of tumour cell proliferation and migration. These inhibitions can be correlated to the interference of NRP1 oligomerization as previously described (Roth et al., 2008) . Interestingly, the addition of pTM-NRP1 before tumour cells transplantation reduced the growth capacity of glioma into the brain. This is reflected by a strong reduction of the tumour bulk and lack of tumour cell dissemination. A recent study shows that Sema3A stimulates glioma cells dispersal by an autocrine mechanism (Bagci et al., 2009) . Thus, it is tempting to speculate that the observed reduction of tumour growth and dissemination in the presence of pTM-NRP1 is the consequence of the inhibition of this mechanism. Strikingly, pTM-NRP1 can also be used to reduce the growth of well-developed tumours. Our data show that pTM-NRP1 can target both the tumour cells and host blood vessels when administrated locally (subcutaneously) or intraperitoneally thereby decreasing tumour expansion. The increasing importance of NRP1 during physiological and pathological angiogenesis recently stimulated the design of various strategies to modulate NRP1 functions. Function-blocking antibodies showed successful application to inhibit tumour growth and vascular remodelling (Gamse et al., 2002; Hong et al., 2007 (Bedjeguelal et al., 2006) showed promising results. However, the peptide used in this study is targeting a very particular domain, the transmembrane domain of NRP1. This domain has been ignored so far because of the lack of efficient tools allowing detailed analysis of this hydrophobic environment. Although initially described for glycophorin-A (Lemmon et al., 1992) , the function of the transmembrane domain is nowadays a growing field of interest because within this particular domain, the targeted motif has crucial implications in diverse pathological situations as shown by the consequence of various point mutations of the TM domain of c-neu receptor (Bargmann and Weinberg, 1988; Weiner et al., 1989) , FGFR3 receptor (Meyers et al., 1995; Webster and Donoghue, 1996; Orian-Rousseau and Ponta, 2008) , FGFR2 (Forbes et al., 2002) or RET (Tessitore et al., 1999) . In all cases, the effects relate to the GxxxG motif Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al (or equivalent small amino-acid-xxx-small amino-acid motif) that is supposed to drive the dimerization of the transmembrane domains (Senes et al., 2004) . This has been clearly shown for APP (Kienlen-Campard et al., (Roth et al., 2008) . We believe that blockade of NRP1 transmembrane domain provides an exquisite therapeutic tool because the biological effects of NRP1 are significantly blocked at picomolar dosage of the peptide (Roth et al., 2008) with a total inhibition of the biological functions of NRP1 obtained at 10
2008) or NRP1
This peptide possesses natural targeting properties due to its biophysical characteristics (hydrophobic) that allow rapid integration to the targeted cell membrane. Moreover, this peptide showed no toxicity for various cell types in culture (including hepatocytes, data not shown) and exhibits a very low immunogenicity profile together with good stability (up to 48 h at the membrane, low sensitivity to proteases when reaching the membrane) compatible with in vivo use and sustained efficacy. More importantly, this peptide acts at the level of endothelial cells to prevent angiogenesis but also inhibits tumour cell proliferation and migration thereby interfering with the three key events favouring tumour growth. Future investigations, together with blood-brain barrier crossing evaluation, will address various strategies devoted to ensure efficient systemic delivery of the peptides for future clinical evaluation. Although 30-50% of the drugs are currently targeting G-protein-coupled receptors, the use of pharmacological agents interfering with the TM domain of bitopic receptors may represent a major advance towards the design of new classes of efficient therapeutic agents for cancer treatment (Bennasroune et al., 2004) or other pathological areas such as neurodegenerative disorders (Marchesi, 2005) . To our knowledge, pTM-NRP1 is the first drug of this kind that shows a therapeutic potential.
Materials and methods
Cell lines
Cells were grown in a 5% CO 2 atmosphere, at 37 1C. C6 cells (ATCC CCL-107) come from rat glioblastoma. They were grown in modified Eagle's medium (Fisher Scientifique, Illkirch, France) with 10% fetal calf serum (SVF; Interchim, Montluc¸on, France), glutamine 0.5 mM (Fisher Scientifique) and antibiotics: 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). Human glioma cell line U373MG (our collection) was cultured in DMEM supplemented with 10% fetal calf serum.
Peptides
Peptides have been synthesized within the Neurosciences IFR37's proteomic facility by Mr B Gue´rold, by automatic peptide synthesis (Fmoc chemistry; Applied System, Courtaboeuf, France), and have been analysed by mass spectrometry. One peptide is the transmembrane sequence of NRP1: ILITIIAMSALGVLLGAVCGVVLYRKR (TM peptide). In the second one, glycines have been replaced by valines: ILITIIAMSALVVLLVAVCVVVLYRKR (mutated TM peptide) (Roth et al., 2008) . Peptides purity estimated by RP-HPLC (Beckman, Roissy, France) is more than 90%. Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al
Ltd. (Oxon, UK) and the MR spectrometer from SMIS Ltd.
(now MR Solutions Ltd., Guildford, UK). We used a fast spin-echo imaging sequence consisting of 15 contiguous coronal slices acquisition with a 3.8 s repetition time. Four echoes were recorded with a 40 ms spin-echo time and a 80 ms effective echo time, the second echo being located at the centre of K space. The slice thickness was 1 mm, and the field of view 40 Â 40 mm 2 with a data matrix 256 Â 256, leading to a resolution of 156 mm. The number of acquisition for each profile was fixed to 2. The resulted acquisition time was approximately 8 min.
In vitro assays (proliferation, migration and angiogenesis) C6 or HUVEC cell aggregates were prepared as previously described (Nasarre et al., 2005) to be grown in the 3D matrix (plasma clot) and treated with VEGF165 (100 ng/ml; R&D, Lille, France). For the proliferation and cell death assay, the cells were incubated at a known density in 60 mm dishes (Dutscher, Brumath, France) (100 Â 10 3 cells). MTT (Promega, Charbonnie`re-les-Bains, France) and tube-like formation assay (in vitro angiogenesis assay; Chemicon) were performed using manufacturer's instructions. Oligomerization assays were performed as previously described (Roth et al., 2008) . RT-PCR were performed at 30 cycles, Tm ¼ 58 1C using NRP1 sense 5 0 -ACAGTGGCACAGGTGATGAC-3 0 and NRP1 anti-sense 5 0 -TCCAGGGCAGATAGGTTC-3 0 primers.
Chick embryo chorioallantoic membrane assay
The CAM assay was performed using Leghorn embryonated eggs. After 4 days incubation, the embryos were transfer to a Petri dish. The CAMs were grown for additional 4 days before deposition of reservoirs in a region containing one large vessel. Reservoirs were filled with 20 ml solution of PBS, pTM-NRP1 (10 À7 M), pTM-NRP1 mut (10 À7 M), VEGF165 (20 mg/ml) or combinations of these factors. After 24 h incubation, microphotographs were taken for quantification of vessel growth. Camera lucida drawing was systematically performed to allow better counting of new blood vessels and sprouting; the entire analysis being performed in blind conditions.
In vivo assays (orthotopic and heterotopic xenografts)
We conducted all in vivo experiments under the supervision and control of the veterinary in charge of the animal facility of the Centre for Neurochemistry (IFR37, Strasbourg) in accordance with the Guide for the Care and Use of Laboratory Animals (NRC, 1996) and the European Directive 86/609. C6 cells (ATCC CCL-107) were stained before transplantation using PKH26 and according to manufacturer's instructions (Sigma). Cells were incubated with peptides (pTM-NRP1 10 À8 M or pTM-NRP1 mut 10 À8 M) before injections for at least 2 h on ice in culture medium (composed of modified Eagle's medium with 5000 U/ml penicillin, 5 mg/ml streptomycin, 200 mM L-glutamine and 10% fetal calf serum). Rats (Janvier, France), all males weighing 250-350 g, were anesthetized by IP injection of a mixture of tiletamine-zolazepam (50 ml/100 g) (Zoletil 100; Virbac, Carros, France), and xylazine (50 ml/100 g) (Rompun 2%; Bayer, Puteaux, France). Cell suspensions were implanted using a stereotaxic set up at the depth of 5 mm, 1 mm anterior to the bregma and 3 mm lateral corresponding to the anterior striatum with a 10 ml Hamilton syringe. After injection, the needle was kept in place for 5 min, then slowly removed at 0.5 mm/15 s. The scalp incision was closed with stainless steal wound clips and the animals allowed recovering under a heat lamp before they are returned to their cage. All injections were performed in the left striatum. After a survival period of 8 days, the animals were killed by a lethal IP injection of pentobarbital before transcardiac perfusion with a prerinse of 100 ml PBS followed by 500 ml of 2% formaldehyde. Heterotopic tumours were produced by injecting 10 6 cells in the flank of pathogen-free Anti-angiogenic effect of pTM-NRP1 in vivo. Histological analysis of tumours. We used isolectin-B4, CD31 and CD34 to stain blood vessels in the tumour bulk. All three markers allowed us to visualize hot spots composed of several blood vessels. We determined number of blood vessels per mm 2 by counting vessels from all hot spots present on three different slices (randomly chosen) from three different tumours (reflecting the smallest, medium and largest tumours of the two groups). Scale bar ¼ 100 mm. **Po0.001.
Inhibition of glioma growth using neuroplin-1 peptide C Nasarre et al BALB/c nu/nu mice (Charles River Laboratories, L'Arbresle, France) maintained in individual cages. For that, the mice, all males or all females, were anesthetized in a Plexiglas box flushed with oxygen containing 3% isoflurane, and then maintained anesthetized by 2% isoflurane inhalation using a facial mask. The cell suspension was taken into a 1 ml syringe and transplanted in the flanks of the mouse subcutaneously (100 ml, 10 6 cells). Live imaging of fluorescent peptide distribution was performed using the NightOwl bioimager (Berthold) equipped with dedicated anaesthesia chamber and appropriate filters for fluorescence detection.
Histology and immunocytochemistry
The brains were postfixed during 2 h at 4 1C and sagittal sections (70 mm) were prepared on a vibratome. One group of sections was mounted in PBS-glycerol (v/v) for microscopic observation, and another one was treated for immunostaining. Ectopic tumours were embedded in PEG before immunoreactions as previously described (Klosen et al., 1993) . Sections were first incubated in PBS containing 5% calf normal serum for 15 min at room temperature to block nonspecific binding sites. A second incubation was performed for 1 h at room temperature and then overnight at 4 1C with appropriate primary antibodies (anti-mouse CD34 or anti-mouse CD31; Clinisciences s.a.s, Montrouge, France) or 30 min at room temperature for Isolectin-B4 (FL-1201; Biovalley, Meaux, France) staining. The sections were washed six times during 5 min in PBS, and were then incubated with secondary antibody coupled to Alexa-488 (1:500; Interchim) for 3 h at room temperature. Sections were washed six times during 5 min in PBS and were finally mounted in PBS-glycerol (v/v) before microscopic analysis. In case of IP injections of RhodpTM-NRP1, tumours were collected 20 min after injections, fixed and sliced for direct observation of slices using appropriate epifluorescence microscope.
Statistics
We performed two independent samples comparison using Student's t-test for n430 and Mann-Whitney analysis for no30 for quantitative data (number of cells, tumour weight, number of vessels, number of branch points). Normal distribution of the values was checked using GraphPad software (Curri, Strasbourg). We performed w 2 -analysis for qualitative data (presence or not of chains of cell migration). A minimum of three independent experiments was performed for in vitro assays (proliferation, migration and angiogenesis). The number of animals used for in vivo analysis takes into account ethical reasons. Sample size calculation was determined by postulating an effect size of À20% (d, differences between two means of tumour volume) given an allocation ratio of one (similar-sized population) and using continuity correction (Uitenbroek, 1997) . We used power ¼ 0.8 and a ¼ 0.05. Thus, the data presented are from one experiment for MRI acquisition composed of three controls and three treated rats (Figure 1a) , three independent experiments composed of three experimental groups of animals for histological analysis of orthotopic brain tumours (giving a total of 12 control, 12 pTM-NRP1-and 7 pTM-NRP1 mut -treated rats, Figure 1b) ; one experiment composed of two groups of 10 mice (giving a total of 19 heterotopic control tumours and 20 heterotopic-treated tumours for U373MG cells, Figure 7 ; one dead animal at day 6 was excluded from control group). In all experiments, animals were randomized before treatment delivery that was performed in blind conditions. The experiment performed with U373MG cells has been stopped after 10 days treatment by decision of the veterinary in charge of the animal facility due to serious impairment of living conditions of the mice of one of the two groups (retrospectively identified as the control group).
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